Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement

Mar

26

Today In Oncology

FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers

Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines

Myelofibrosis Treatment Landscape Is Poised for Change

AI Model Classifies Challenging Thymic Epithelial Tumors

Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk

Advertisement

© 2026 HSP News Service, L.L.C.